Alliance Life Sciences CEO, Alan Crowther, will join health economist Carina Schey to present at this year’s World Orphan Drug Congress in Geneva, Switzerland on November 12.
Topic: New Orphan Drug Pricing Trends and Risks
There is a global trend to drive down the cost of drugs and several high-priced orphan drugs have raised concerns about the budget impact on the total pharmaceutical spend of the orphan category as a whole.
This presentation will evaluate current pricing approaches and trends, as well as consider where orphan drug pricing may be 3 to 5 years out, and discuss the impact this could have on manufacturers, payers and access.
Attendees will learn:
- Orphan drug pricing trends and expectations of what is coming
- Pricing models in use today to support orphan drug pricing decisions
- Pricing challenges facing manufacturers and payers
- Key considerations to avoid access problems in the future
To learn more and register now, visit http://www.terrapinn.com/conference/world-orphan-drug-congress